privileged structure

Some shapes seem to be welcomed almost everywhere, like a universal adapter that fits many sockets. A privileged structure is a molecular scaffold that, with different decorations hung on it, has repeatedly produced active ligands against many unrelated drug targets — as if the core itself were unusually good at meeting proteins halfway.

The term was coined by Ben Evans and colleagues in 1988 to describe scaffolds such as the benzodiazepine and biphenyl frameworks that turned up again and again in ligands across receptor families. The usual explanation is that these cores present a rigid, well-defined three-dimensional display of aromatic and other groups that complements common features of many binding pockets; the surrounding substituents then tune which specific target is hit. Other often-cited examples include the indole, benzimidazole, and spiro-piperidine scaffolds.

Privileged structures are valuable starting points and feature heavily in screening library design, because building around them raises the odds of finding hits. The honest caveat is that the privilege is statistical and not magical: the same recurring cores also tend to be promiscuous, can bring along baggage like off-target activity or hERG liability, and their frequent appearance partly reflects which chemistries are easy to make. They are a head start, not a guarantee of selectivity or developability.